Capstone Therapeutics (CAPS) Misses Q2 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St set for muted open as tech stocks take a breather
- Oil slips on rise in Middle East crude exports and G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
Tweet
Share
E-mailGet Alerts CAPS Hot Sheet
Join SI Premium – FREE
Capstone Therapeutics (NASDAQ: CAPS) reported Q2 EPS of ($0.13), $0.16 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $12.85 million versus the consensus estimate of $15.05 million.
For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- National Bank Holdings (NBHC) PT Lowered to $43 at DA Davidson
- StoneX Reiterates Buy Rating on Cinemark Holdings (CNK)
- RXO shares soar as C.H. Robinson announces $5.8B cash and stock buyout
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
